RxDoctor Payments Data

Tonia Vinton, MD

Internal Medicine · Dallas, TXNPI 1861602559

Payments from drug & device makers

$5,520in general payments, 2019–2025

Across 89 payments — averaging $62.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • Rhythm Pharmaceuticals, Inc.$257
  • Lilly USA, LLC$207
  • Astellas Pharma US Inc$170
  • Corcept Therapeutics$112
  • Apollo Endosurgery US Inc$109
  • plus $292 from 9 others

What the payments were for

  • Consulting fees$2,13039%
  • Travel & lodging$91817%
  • Food & beverage$2,33642%
  • Education$1362%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,520 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,008
Medicare patients
114
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide172$232,606
OzempicSemaglutide110$178,324
WegovySemaglutide43$64,923
JardianceEmpagliflozin32$32,092
Bupropion XlBupropion Hcl83$2,134
Naltrexone Hcl24$1,492
Metformin Hcl ErMetformin Hcl67$679
Topiramate24$171
Ondansetron Hcl13$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$4,372$243,247153 claims
Lilly USA, LLCMounjaro$207$232,606172 claims
Boehringer IngelheimJardiance$16$32,09232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →